启迪药业(000590) - 2014 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company was -¥628,063.19, a decrease of 96.08% year-on-year[4] - Operating revenue for the reporting period was ¥50,262,941.27, down 2.49% compared to the same period last year[4] - Basic earnings per share were -¥0.0028, a decrease of 96.10% compared to the same period last year[5] - The weighted average return on net assets was -0.23%, down from 4.49% in the previous year[5] - Main business revenue decreased by ¥82,210,032.41, a decline of 36.31% mainly due to a drop in traditional Chinese medicine sales and production halts at the pharmaceutical company[14] - Net profit increased by ¥324,755.82, a rise of 31.56% attributed to reduced period expenses and increased investment income[14] Cash Flow - The net cash flow from operating activities was -¥56,596,729.62, a significant decrease of 1,197.47% year-on-year[4] - Cash flow from operating activities decreased by ¥52,234,646.67, a significant drop of 1197.47% due to reduced cash received from sales of goods and services[14] - Cash flow from financing activities increased by ¥68,562,392.83, a rise of 98.78% mainly due to increased bank borrowings during the period[14] Assets and Liabilities - Total assets at the end of the reporting period reached ¥559,406,406.28, an increase of 1.24% compared to the end of the previous year[4] - Accounts receivable increased by ¥21,687,143.43, a rise of 30.62% due to increased bill settlement business[13] - Prepayments rose by ¥2,606,906.11, a significant increase of 90.57% mainly due to higher equipment prepayments[13] - Other receivables surged by ¥25,886,387.05, an increase of 300.50% primarily for payments related to the acquisition of Tongdexiang[13] - Construction in progress increased by ¥11,497,692.09, a dramatic rise of 13907.94% due to substantial investment in supporting projects[13] - Short-term borrowings increased by ¥50,000,000.00, a 100.00% rise as the Chinese medicine company took on new bank loans[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,422[8] - The largest shareholder, Unisplendour Corporation Limited, held 18.61% of the shares, totaling 41,561,844 shares[8] Government Subsidies and Accounting Adjustments - The company recognized government subsidies amounting to ¥890,000.00 during the reporting period[6] - The company made adjustments to its accounting policies, resulting in an increase of ¥6,029,950.78 in available-for-sale financial assets[12] Business Costs - Main business costs fell by ¥40,249,428.87, a decrease of 36.99% primarily due to the decline in main business revenue[14]